The new indication for ramoximab has been approved, adding vitality to the second-line treatment of advanced liver cancer
Time of Update: 2022-10-21
*For medical professionals onlyThe approval of ramoximab will provide a new option for the second-line treatment of advanced liver cancer!On October 8, 2022, the National Medical Products Administration (NMPA) officially approved the latest indication for ramucirumab (trade name: Hopeful Choice), namely, for the treatment of patients with hepatocellular carcinoma (HCC) who have previously received sorafenib treatment and have a alpha-fetoprotein (AFP) ≥ 400 ng/mL.
Nat Chem Biol Small Molecules Targeting Biomolecular Agglomerates: Jidong Zhu/Guangya Zhu team discovered a new strategy for targeting AR phase separation for prostate cancer
Time of Update: 2022-10-20
Since AR promotes its transcriptional activity through NTD-mediated phase separation, the authors hope to inhibit the transcriptional activity of AR through liquid-liquid phase separation of small molecules targeting AR and overcome the problem of resistance to AR antagonist drugs caused by mutations or deletions of LBD(Figure 3).
Fujian strives to receive 15 million tons of LNG by 2025
Time of Update: 2022-10-19
Commodity oil storage facilities to enhance oil storage capacity At the same time, the "Plan" proposes to focus on promoting the construction of Sinopec's Gulei crude oil commercial reserve base project and Gulei and other underground oil commercial storage projects, encouraging private capital to participate in the construction of oil reserves and supporting enterprise construction in combination with the layout requirements for the development of the petrochemical industry.
Lancet Haematol: ibethromide plus dexamethasone for severely pretreated late relapsed or refractory multiple myeloma
Time of Update: 2022-10-19
1016/S2352-3026(22)00290-3 Original source:Lonial S, Popat R, Hulin C, et al.
Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial [published online ahead of print, 2022 Oct 6].
The latest progress of Quanzhou Guoheng PDH project and Ningbo Formosa PDH project
Time of Update: 2022-10-16
The three heat exchangers were hoisted sequentially from north to south, and the final safe and smooth The completion of the hoisting indicates that the project will fully enter the stage of pipeline installation Aiming at the limitations of the on-site operation site, the project department compiled a detailed hoisting plan through the preliminary on-site measurement and computer lofting simulation, and selected a 700-ton crawler crane with a counterweight to prevent overhanging.
[One case per day] Chinese Journal of Radiology: A case of primary neuroendocrine cancer of the spleen
Time of Update: 2022-10-12
Fig. 1 Ultrasound shows splenomegaly, see slightly higher echo to implement the mass, the boundary is unclear, the blood flow signal is detected, the vascular structure disorder of the spleen hilar i
Emergency conversion to 10,000 tons
Time of Update: 2022-08-21
China Coal Group's "13th Five-Year" planning projects include: Ordos Tuke Industrial Zone's second-phase project with an annual output of 1 million tons of methanol; Shaanxi Yanchang China Coal Yulin Energy and Chemical Co.
Annual Analysis of Pharmaceutical R&D Trends in 2022
Time of Update: 2022-08-15
. "Different from Hengrui's independent research and development, the expansion of Fosun's drug pipeline mainly relies on the introduction of drug technologies from partners, including the introduction of BioNTech SE's mRNA new crown vaccine technology," said Ian Lloyd, senior director of Pharmaprojects, in the "2022 Annual Pharmaceutical R&D Trends Year".
Time of Update: 2022-06-06
Thin layer plate silica gel G plateDeveloping agent chloroform-ethanol-water (8: 2: 1)After checking the color of 2% p-dimethylaminobenzaldehyde in 40% sulfuric acid solution, check under sunlight and ultraviolet light (365nm)2.
Thin layer plate silica gel G plateDeveloping agent chloroform-methanol-acetic acid (10:2:0.
Ascentage Pharma Completes First Patient Dosing in China's Key Registration Phase II Clinical Trial of Bcl-2 Selective Inhibitor APG-2575 for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small
Time of Update: 2022-04-26
Ascentage Pharma (6855. HK), a leading biopharmaceutical company dedicated to the development of innovative drugs in the therapeutic areas of oncology, hepatitis B and aging-related diseases, announc
With the continuous expansion of the biopharmaceutical market, the domestic substitution of biopharmaceutical equipment will accelerate
Time of Update: 2022-04-15
The biopharmaceutical market continues to expand, and the domestic substitution of biopharmaceutical equipment is accelerating (Photo source: Pharmaceutical Network) Various regions are vigorously developing the biopharmaceutical industry , the province's bio-pharmaceutical industry operating income to achieve the goal of "protecting four and competing for five" .
Biohaven and Bioshin's Pivotal Trial of rimegepant (NURTEC® ODT) for Acute Treatment of Migraine Hits Primary Endpoint Press Release
Time of Update: 2022-03-07
- is the first oral calcitonin gene-related peptide NURTEC® ODT (CGRP) receptor antagonist to show positive results in a pivotal trial in Asia Pacific, with more than 100 million patients suffering from migraine in China and South Korea alone .
Sanhe Pharmaceutical's third-generation EGFR-TKI inhibitor "Oritinib" applied for listing
Time of Update: 2022-02-23
The trial results showed that among the 59 subjects with positive EGFR T790M mutation, the ORR assessed by BICR was 57.
Hansoh Ametinib is the first domestically produced third-generation EGFR-TKI approved for marketing in China, and has been approved by the NMPA for first-line and second-line treatment of NSCLC .
Domestic PD-(L)1 explodes in 2021, and imported drugs face extinction
Time of Update: 2022-01-09
In November of this year, Professor Lu Shun from the Thoracic Hospital of Shanghai Jiaotong University reported at the ESMO Asia conference the interim analysis results of the randomized, double-blind, multicenter phase III study ORIENT-31 (NCT03802240), showing that Sintilizumab is combined Bevacizumab biosimilars and chemotherapy for EGFR-positive locally advanced or metastatic non-squamous NSCLC patients who have progressed through EGFR-TKI treatment have obtained significant and clinically significant PFS prolongation .
Datong City Market Supervision Administration Announcement on Food Safety Supervision Sampling Inspection Information in 2021 (No. 21
Time of Update: 2021-12-26
The aluminum residue (dry sample, calculated as Al) in the round vermicelli sold by Li Shubing Fruit and Vegetable Shop (No. 53, Beilisheng Lane, Pingcheng District), Pingcheng District, Datong City, does not meet the national food safety standards .